Hence, through a detailed phenotypic characterization, Messias and colleagues reinforce the current understanding that the anti-MOG antibody is not a predictor of progression to multiple sclerosis or a marker for neuromyelitis optica in patients negative for the anti-AQP4 antibody, but rather an indicator of a distinct disease entity.2 This evidence concerns the gene MOG and neuromyelitis optica.